1200w,https://media.npr.org/assets/img/2023/03/31/gettyimages-1236946488-300e6a5c28ebcae4331ba2769a7d0055aeee8128-s1600-c85.jpg 1600w,https://media.npr.org/assets/img/2023/03/31/gettyimages-1236946488-300e6a5c28ebcae4331ba2769a7d0055aeee8128-s1800-c85.jpg 1800w" sizes="(min-width: 1300px) 763px, (min-width: 1025px) calc(100vw - 496px), (min-width: 768px) calc(100vw - 171px), calc(100vw - 30px)" type="image/jpeg"/>

Narcan, a nasal spray version of the drug Naloxone, rapidly reverses the effects of an opioid overdose. YUKI IWAMURA/AFP via Getty Images hide caption

toggle caption
YUKI IWAMURA/AFP via Getty Images

Narcan, a nasal spray version of the drug Naloxone, rapidly reverses the effects of an opioid overdose.

YUKI IWAMURA/AFP via Getty Images

The FDA has approved over-the-counter sales of Narcan, a nasal spray version of the life-saving medication naloxone. The medication is known for its ability to rapidly reverse an opioid overdose.

The FDA's move will make Narcan more widely available than ever before. But experts say this is just one step in the right direction, when it comes to preventing overdose deaths.

NPR's Ailsa Chang speaks with Nabarun Dasgupta, a senior scientist at the University of North Carolina who has been studying opioid overdose prevention and addiction treatment since 2002, about what this means for the opioid epidemic.

In participating regions, you'll also hear a local news segment to help you make sense of what's going on in your community.

Email us at This email address is being protected from spambots. You need JavaScript enabled to view it..

This episode was produced by Erika Ryan with engineering by Maggie Luthar. It was edited by William Troop. Our executive producer is Sami Yenigun.

Northern California
Public Media Newsletter

Get the latest updates on programs and events.